Financing ·
Vivos Therapeutics, Inc. closed a $2.1 million PIPE offering on June 30, 2026, selling 3,608,496 units consisting of…
VVOSVivos Therapeutics, Inc.
Vivos Therapeutics, Inc. closed a $2.1 million PIPE offering on June 30, 2026, selling 3,608,496 units consisting of Series A Convertible Preferred Stock and common stock purchase warrants. The offering included $1,000,000 in new cash proceeds and $1,000,000 from the conversion of a previously funded bridge promissory note. The company established a new class of Series A Convertible Preferred Stock with a stated value of $0.456 per share. Vivos Therapeutics, Inc. is a biotechnology company focused on developing medical technology for gastrointestinal health.